Baiano Cinzia, Somma Teresa, Franca Raduan Ahmed, Di Costanzo Marianna, Scala Maria Rosaria, Cretella Pasquale, Esposito Felice, Cavallo Luigi Maria, Cappabianca Paolo, Solari Domenico
Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Università degli Studi di Napoli "Federico II", Naples, Italy.
Pathology Section, Department of Advanced Biomedical Sciences, Università degli Studi di Napoli "Federico II", Naples, Italy.
Front Oncol. 2022 Jul 28;12:975738. doi: 10.3389/fonc.2022.975738. eCollection 2022.
Endonasal endoscopic surgery has changed the treatment perspectives for different lesions of the hypothalamic-pituitary region. The metastases of the hypothalamic-pituitary region represent 0.4% of all intracranial metastatic tumors and account for only 1.8% of surgically managed pituitary lesions. The aim of tshis study is to describe a single-center institutional experience with 13 cases of hypothalamic-pituitary metastasis focused on presurgical workup, the evolution of the surgical technique, and postsurgical management according to our protocols, showing effects on progression-free and overall survival rates for this relatively uncommon location.
We retrospectively reviewed the whole series of patients that received the endoscopic endonasal approach at the Division of Neurosurgery at the University of Naples "Federico II" undergoing surgery from January 1997 to December 2021. We identified 13 cases whose pathology reports revealed a metastatic lesion. Statistical analysis was performed to determine the Kaplan-Meier survival function and assess for log-rank differences in survival based on gender, surgical treatment, and postoperative therapy (-value < 0.02*).
The pathology report disclosed lung adenocarcinoma (six cases, 46%), breast adenocarcinoma (two cases, 15.4%), clear cell renal carcinoma (one case, 7%), melanoma (one case, 7%), colorectal adenocarcinoma (one case, 7%), uterine cervix carcinoma (one case, 7%), and follicular thyroid carcinoma (one case, 7%). A standard endoscopic endonasal approach was performed in 10 patients (76.9%), while an extended endonasal procedure was performed in only three cases (23%). Biopsy was the surgical choice in five patients with infiltrative and invasive lesions and a poor performance status (38%), while in the cases where neurovascular decompression was necessary, a subtotal resection was achieved in five patients (38%) and partial resection in three patients (23%). Recovery of visual field defect was observed in six of seven patients with visual loss (85.7%), improvement of oculomotor nerve palsy occurred in four of seven patients with this defect (57.1%), while the impairment of oculomotor palsy was observed in three patients (42.9%). Visual function was stable in the other patients. The median progression-free survival and overall survival were 14 and 18 months, respectively. There were statistically significant differences in PFS and OS in patients who underwent adjuvant radiotherapy (p=0.019 is referred to OS and p=0.017 to PFS, respectively; -value = 0.02).
The endoscopic endonasal approach is a viable approach for the management of hypothalamic-pituitary metastases as this surgery provides an adequate opportunity to obtain tissue sample and neurovascular decompression, both being crucial for continuing the integrated adjuvant therapy protocols.
鼻内镜手术改变了下丘脑 - 垂体区域不同病变的治疗前景。下丘脑 - 垂体区域的转移瘤占所有颅内转移瘤的0.4%,仅占手术治疗的垂体病变的1.8%。本研究的目的是描述单中心机构对13例下丘脑 - 垂体转移瘤的经验,重点关注术前检查、手术技术的演变以及根据我们的方案进行的术后管理,展示对这个相对不常见部位的无进展生存率和总生存率的影响。
我们回顾性分析了1997年1月至2021年12月在那不勒斯“费德里科二世”大学神经外科接受内镜鼻内入路手术的所有患者系列。我们确定了13例病理报告显示为转移瘤的病例。进行统计分析以确定Kaplan - Meier生存函数,并根据性别、手术治疗和术后治疗评估生存的对数秩差异(P值<0.02*)。
病理报告显示肺腺癌(6例,46%)、乳腺腺癌(2例,15.4%)、透明细胞肾癌(1例,7%)、黑色素瘤(1例,7%)、结肠腺癌(1例,7%)、子宫颈癌(1例,7%)和滤泡性甲状腺癌(1例,7%)。10例患者(76.9%)采用了标准的内镜鼻内入路,而仅3例患者(23%)采用了扩大鼻内手术。活检是5例浸润性和侵袭性病变且身体状况较差患者(38%)的手术选择,而在需要进行神经血管减压的病例中,5例患者(38%)实现了次全切除,3例患者(23%)实现了部分切除。7例视力丧失患者中有6例(85.7%)视野缺损得到恢复,7例动眼神经麻痹患者中有4例(57.1%)该缺陷得到改善,而3例患者(42.9%)出现动眼神经麻痹加重。其他患者的视觉功能稳定。无进展生存期和总生存期的中位数分别为14个月和18个月。接受辅助放疗的患者在无进展生存期和总生存期方面存在统计学显著差异(分别将P = 0.019用于总生存期,P = 0.017用于无进展生存期;P值 = 0.02)。
内镜鼻内入路是治疗下丘脑 - 垂体转移瘤的一种可行方法,因为该手术为获取组织样本和进行神经血管减压提供了充分机会,这两者对于继续综合辅助治疗方案至关重要。